Form D — Aligos Therapeutics, Inc.
0000950123-25-002925 · filed Feb 28, 2025
Figures are issuer-reported and describe stored filings. Data coverage and methodology.
Check this disclosure on SEC EDGAR · More Biotechnology filings
Offering
- Industry
- Biotechnology
- Exemptions
- Rule 506(b)
- Reported offering amount
- $105,003,206
- Reported amount sold
- $105,003,206
- Minimum investment
- $0
- Investors
- —
- Sales commission
- —
- Finders' fees
- —
Issuer
- Name
- Aligos Therapeutics, Inc.
- CIK
- 1799448
- Entity
- Corporation
- Jurisdiction
- DELAWARE
- Year incorporated
- —
- Address
- One Corporate Dr., 2nd Floor
South San Francisco, California 94080 - Phone
- (800) 466-6059
Related persons
May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.
-
Lawrence M. Blatt · Executive OfficerSouth San Francisco, California Find on LinkedIn ↗
-
Lesley Ann Calhoun · Executive OfficerSouth San Francisco, California Find on LinkedIn ↗
-
K. Peter Hirth · DirectorSouth San Francisco, California Find on LinkedIn ↗
-
Margarita Chavez · DirectorSouth San Francisco, California Find on LinkedIn ↗
-
Carole Nuechterlein · DirectorSouth San Francisco, California Find on LinkedIn ↗
-
James Scopa · DirectorSouth San Francisco, California Find on LinkedIn ↗
-
Bridget Martell · DirectorSouth San Francisco, California Find on LinkedIn ↗
-
Heather Preston · DirectorSouth San Francisco, California Find on LinkedIn ↗
-
Julian Symons · Executive OfficerSouth San Francisco, California Find on LinkedIn ↗
-
Hardean Achneck · Executive OfficerSouth San Francisco, California Find on LinkedIn ↗
View the original filing on SEC EDGAR ↗